Quality of life assessment in adults with type 1 Gaucher disease

Quality of Life Research

Volumn 8, Issue 3, 1999, Pages 263-268

  Masek, Bruce J ^a,b   Sims, Katherine B ^b   Bove, Catherine M ^b   Korson, Mark S ^a   Short, Priscilla ^c   Norman, Dennis K ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c AMERICAN MEDICAL ASSOCIATION   (United States)

Author keywords

Enzyme replacement therapy; Gaucher disease; Quality of life

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HEALTH STATUS; HUMAN; MALE; MOOD; PATIENT ATTITUDE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 0032811874     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008859420641     Document Type: Article

References (26)

1. 1. Beutler E. Gaucher disease: new molecular approaches to diagnosis and treatment. Science 1992; 256: 794-799.
2. 2. Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency -macrophage-targeted glucocerebrosidase for Gaucher's disease. New Eng J Med 1991; 324: 1464-1470.
3. 3. Zimran A, Kay A, Gelbart T et al. Gaucher disease: clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine 1992; 71: 337-353.
4. 4. NIH Technology Assessment Panel on Gaucher Disease. Gaucher disease: current issues in diagnosis and treatment. J Amer Med Assoc 1996; 275: 548-553.
5. 5. Mankin HJ, Doppelt SH, Rosenberg AE, Barranger JA. Metabolic bone disease in patients with Gaucher's disease. In: Avioli LV, Krane SM (Eds). Metabolic bone disease and clinically related disorders. Philadelphia: WB Saunders, 1990: 730-752.
6. 6. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990; 87: 1913-1916.
7. 7. Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993; 82: 408-416.
8. 8. Clarke AE, Goldstein MK, Michelson D, Garber AM, Lenart LA. The effect of assessment method and respondent population on utilities elicited for Gaucher disease. Qual Life Res 1997; 6: 169-182.
9. 9. Garber AM. No price too high? New Engl J Med 1992; 327: 1676-1678.
10. 10. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Annals of Internal Medicine 1993; 118: 622-629.
11. 11. Lubeck DP, Litwin JM, Henning JM, Carroll PR. Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database, Qual Life Res 1997; 6: 385-392.
12. 12. Sutherland HJ, Till JE. Quality of life assessments and levels of decision making: differentiating objectives. Qual Life Res 1993; 2: 297-303.
13. 13. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: New England Medical Center, The Health Institute, 1993.
14. 14. Derogatis LR. SCL-90-R: administration, scoring and procedures manual. Minneapolis: National Computer Systems, 1994.
15. 15. Mosteller F, Ware JE, Levine S. Final panel: comments on the conference on advances in health status assessment. Medical Care 1989; 27: S283-294.
16. 16. Cohen J. Statistical power for the behavioral sciences. Hillsdale, NJ: Lawrence Earlbaum Associates, 1988.
17. 17. Rosenthal DI, Doppelt SH, Mankin HJ et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995; 96: 629-637.
18. 18. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in type 1 Gaucher disease. Journal of Bone and Mineral Research 1996; 11: 1801-1807.
19. 19. Croog SH, Levine S, Testa MA et al. The effects of antihypertensive therapy on the quality of life. New Engl J Med 1986; 314: 1157-1664.
20. 20. Lenderking WR, Gelber RD, Cotton DJ et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. New Engl J Med 1994; 330: 738-743.
21. 21. Meyer KB, Espindle DM, DeGiacomo JM, Jenuleson CS, Kurtin PS, Davies AR. Monitoring dialysis patients' health status. Amer J Kidney Dis 1994; 24: 267-279.
22. 22. Derogatis LR, Derogatis MF. SCL-90-R and the BSI. In: Spilker B (ed). Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996: 323-335.
23. 23. Patrick DL, Deyo RA. Generic and diseae-specific measures in assessing health status and quality of life. Medical Care 1989; 27: S217-S232.
24. 24. Cella D, Tulsky S. Measuring quality of life today: methodological aspects. Oncology 1990; 4: 29-38.
25. 25. Sprangers MAG, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992; 45: 743-760.
26. 26. Bech P. Quality of life measurements in chronic disorders. Psychotherapy and Psychosomatics 1993; 59: 1-10.